Concise Review: Process Development Considerations for Cell Therapy

Author:

Campbell Andrew12,Brieva Thomas13,Raviv Lior14,Rowley Jon15,Niss Knut16,Brandwein Harvey17,Oh Steve18,Karnieli Ohad14

Affiliation:

1. International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada

2. Thermo Fisher Scientific, Inc., Grand Island, New York, USA

3. Celgene Cellular Therapeutics, Warren, New Jersey, USA

4. Pluristem Therapeutics Inc., Haifa, Israel

5. Rooster Bio Inc., Frederick, Maryland, USA

6. Novartis Pharmaceuticals, Morris Plains, New Jersey, USA

7. Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA

8. Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore

Abstract

Abstract The development of robust and well-characterized methods of production of cell therapies has become increasingly important as therapies advance through clinical trials toward approval. A successful cell therapy will be a consistent, safe, and effective cell product, regardless of the cell type or application. Process development strategies can be developed to gain efficiency while maintaining or improving safety and quality profiles. This review presents an introduction to the process development challenges of cell therapies and describes some of the tools available to address production issues. This article will provide a summary of what should be considered to efficiently advance a cellular therapy from the research stage through clinical trials and finally toward commercialization. The identification of the basic questions that affect process development is summarized in the target product profile, and considerations for process optimization are discussed. The goal is to identify potential manufacturing concerns early in the process so they may be addressed effectively and thus increase the probability that a therapy will be successful. Significance The present study contributes to the field of cell therapy by providing a resource for those transitioning a potential therapy from the research stage to clinical and commercial applications. It provides the necessary steps that, when followed, can result in successful therapies from both a clinical and commercial perspective.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

Reference23 articles.

1. Current Trends in Monoclonal Antibody Development and Manufacturing

2. Emerging challenges in cell therapy manufacturing: Solutions from monoclonal antibodies;Jones;Bioprocess Int,2012

3. Concise review: Guidance in developing commercializable autologous/patient-specific cell therapy manufacturing;Eaker;Stem Cells Translational Medicine,2013

4. Roadmap for implementation of quality by design (QbD) for biotechnology products;Rathore;Trends Biotechnol,2009

Cited by 103 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3